Medical device having lithium-ion battery

ABSTRACT

An exemplary embodiment relates to a medical device that includes a rechargeable lithium-ion battery for providing power to the medical device. The lithium-ion battery includes a positive electrode comprising a current collector, a first active material, and a second active material. The lithium-ion battery also includes a negative electrode comprising a current collector and a third active material, the third active material comprising a titanate material. The first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions. The second active material exhibits charging and discharging capacity below a corrosion potential of the current collector of the negative electrode and above a decomposition potential of the first active material.

BACKGROUND

The present invention relates generally to the field of lithium batteries. Specifically, the present invention relates to lithium-ion batteries that are relatively tolerant to over-discharge conditions and medical devices which utilize such batteries.

Lithium-ion batteries include a positive current collector (e.g., aluminum such as an aluminum foil) having an active material provided thereon (e.g., LiCoO₂) and a negative current collector (e.g., copper such as a copper foil) having an active material (e.g., a carbonaceous material such as graphite) provided thereon. Together the positive current collector and the active material provided thereon are referred to as a positive electrode, while the negative current collector and the active material provided thereon are referred to as a negative electrode.

FIG. 1 shows a schematic representation of a portion of a lithium-ion battery 10 such as that described above. The battery 10 includes a positive electrode 20 that includes a positive current collector 22 and a positive active material 24, a negative electrode 30 that includes a negative current collector 32 and a negative active material 34, an electrolyte material 40, and a separator (e.g., a polymeric microporous separator, not shown) provided intermediate or between the positive electrode 20 and the negative electrode 30. The electrodes 20, 30 may be provided as relatively flat or planar plates or may be wrapped or wound in a spiral or other configuration (e.g., an oval configuration). The electrode may also be provided in a folded configuration.

During charging and discharging of the battery 10, lithium ions move between the positive electrode 20 and the negative electrode 30. For example, when the battery 10 is discharged, lithium ions flow from the negative electrode 30 to the to the positive electrode 20. In contrast, when the battery 10 is charged, lithium ions flow from the positive electrode 20 to the negative electrode 30.

FIG. 2 is a graph 100 illustrating the theoretical charging and discharging behavior for a conventional lithium-ion battery. Curve 110 represents the electrode potential versus a lithium reference electrode for a positive electrode that includes an aluminum current collector having a LiCoO₂ active material provided thereon, while curve 120 represents the electrode potential versus a lithium reference electrode for a negative electrode that includes a copper current collector having a carbonaceous active material provided thereon. The difference between curves 110 and 120 is representative of the overall cell voltage.

As shown in FIG. 2, upon initial charging to full capacity, the potential of the positive electrode, as shown by curve 110, increases from approximately 3.0 volts to a point above the corrosion potential of copper used to form the negative electrode (designated by dashed line 122). The potential of the negative electrode decreases from approximately 3.0 volts to a point below the decomposition potential of the LiCoO₂ active material provided on the aluminum current collector (designated by dashed line 112). Upon initial charging, the battery experiences an irreversible loss of capacity due to the formation of a passive layer on the negative current collector, which may be referred to as a solid-electrolyte interface (“SEI”). The irreversible loss of capacity is shown as a ledge or shelf 124 in curve 120.

One difficulty with conventional lithium-ion batteries is that when such a battery is discharged to a point near zero volts, it may exhibit a loss of deliverable capacity and corrosion of the negative electrode current collector (copper) and possibly of the battery case, depending on the material used and the polarity of the case. As shown in FIG. 2, after initial charging of the battery, a subsequent discharge of the battery in which the voltage of the battery approaches zero volts (i.e., zero percent capacity) results in a negative electrode potential that follows a path designated by dashed line 126. As shown in FIG. 2, the negative electrode potential levels off or plateaus at the copper corrosion potential of the negative current collector (approximately 3.5 volts for copper and designated by dashed line 122 in FIG. 2).

The point at which the curves 110 and 120 cross is sometimes referred to as the zero voltage crossing potential, and corresponds to a cell voltage that is equal to zero (i.e., the difference between the two curves equals zero at this point). Because of the degradation of the copper current collector which occurs at the copper corrosion potential, the copper material used for the negative current collector corrodes before the cell reaches a zero voltage condition, resulting in a battery that exhibits a dramatic loss of deliverable capacity.

While FIG. 2 shows the theoretical charging and discharging behavior of a battery that may experience corrosion of the negative current collector when the battery approaches a zero voltage configuration, it should be noted that there may also be cases in which the active material on the positive current collector may degrade in near-zero-voltage conditions. In such cases, the theoretical charging and discharging potential of the positive electrode versus a lithium reference electrode would decrease to the decomposition potential of the positive active material (shown as line 112 in FIG. 2), at which point the positive active material would decompose, resulting in potentially decreased protection against future over-discharge conditions.

Because damage to the lithium-ion battery may occur in the event of a low voltage condition, conventional lithium-ion batteries may include protection circuitry and/or may be utilized in devices that include protection circuitry which substantially reduces the current drain from the battery (e.g., by disconnecting the battery).

The medical device industry produces a wide variety of electronic and mechanical devices for treating patient medical conditions. Depending upon the medical condition, medical devices can be surgically implanted or connected externally to the patient receiving treatment. Clinicians use medical devices alone or in combination with drug therapies and surgery to treat patient medical conditions. For some medical conditions, medical devices provide the best, and sometimes the only, therapy to restore an individual to a more healthful condition and a fuller life.

It may be desirable to provide a source of battery power for such medical devices, including implantable medical devices. In such cases, it may be advantageous to provide a battery that may be recharged. It may also be advantageous to provide a battery that may be discharged to a near zero voltage condition without substantial risk that the battery may be damaged (e.g., without corroding one of the electrodes or the battery case, decomposing the positive active material, etc.) such that the performance of the battery is degraded in subsequent charging and discharging operations.

It would be advantageous to provide a battery (e.g., a lithium-ion battery) that may be discharged to near zero volts without producing a subsequent decrease in the amount of deliverable capacity or producing a corroded negative electrode or battery case. It would also be advantageous to provide a battery that compensates for the irreversible loss of capacity resulting from initial charging of the battery to allow the battery to be used in near zero voltage conditions without significant degradation to battery performance. It would also be advantageous to provide a medical device (e.g., an implantable medical device) that utilizes a battery that includes any one or more of these or other advantageous features.

SUMMARY

An exemplary embodiment relates to a medical device that includes a rechargeable lithium-ion battery for providing power to the medical device. The lithium-ion battery includes a positive electrode comprising a current collector, a first active material, and a second active material. The lithium-ion battery also includes a negative electrode comprising a current collector and a third active material, the third active material comprising a titanate material. The first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions. The second active material exhibits charging and discharging capacity below a corrosion potential of the current collector of the negative electrode and above a decomposition potential of the first active material.

Another exemplary embodiment relates to a device for providing at least one of a therapeutic treatment and a diagnostic function to a patient. The device includes a rechargeable battery for providing power to the device. The battery includes a positive current collector and a negative current collector. An active material layer is provided on the positive current collector. The active material layer includes a first active material for doping and de-doping lithium ions and a second active material for doping and de-doping lithium ions. The second active material exhibits charge and discharge capacity below a corrosion potential of the negative current collector, and is lithiated such that it includes electrochemically active lithium. A third active material comprising a lithium titanate material is provided on the negative current collector for doping and de-doping lithium ions.

Another exemplary embodiment relates to a system for providing at least one of a therapeutic treatment and a diagnostic function to a patient. The system includes a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged. The lithium-ion battery includes a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon. The lithium-ion battery also includes a positive electrode having a current collector including aluminum and having a primary active material and a secondary active material provided on at least one side thereof. The secondary active material includes a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material.

Another exemplary embodiment relates to a method of treating a medical condition of a patient that includes providing at least a portion of a medical device in contact with the patient and providing power to the medical device from a battery such that the medical device provides a therapeutic treatment to the patient. The battery includes a positive electrode having a positive current collector, a first active material, and a second active material. The battery also includes a negative electrode comprising a negative current collector and a third active material, the third active material comprising a lithium titanate material. The first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions. The second active material exhibits charging and discharging capacity below a corrosion potential of the negative current collector and above a decomposition potential of the first active material.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic cross-sectional view of a conventional lithium-ion battery.

FIG. 2 is a graph illustrating the theoretical charging and discharging behavior for a conventional lithium-ion battery such as that shown schematically in FIG. 1.

FIG. 3 is a schematic cross-sectional view of a portion of a lithium-ion battery according to an exemplary embodiment.

FIG. 4 is a schematic cross-sectional view of a portion of a lithium-ion battery according to another exemplary embodiment.

FIG. 5 is a graph illustrating the theoretical charging and discharging behavior for a lithium-ion battery such as that shown in FIG. 3.

FIG. 6 is a schematic view of a system in the form of an implantable medical device implanted within a body or torso of a patient.

FIG. 7 is schematic view of another system in the form of an implantable medical device.

DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS

With reference to FIG. 3, a schematic cross-sectional view of a portion of a lithium-ion battery 200 is shown according to an exemplary embodiment. According to an exemplary embodiment, the battery 200 has a rating of between approximately 10 and 1000 milliampere hours (mAh). According to another exemplary embodiment, the battery has a rating of between approximately 100 and 400 mAh. According to another exemplary embodiment, the battery is an approximately 300 mAh battery. According to another exemplary embodiment, the battery is an approximately 75 mAh battery.

The battery 200 includes at least one positive electrode 210 and at least one negative electrode 220. The electrodes may be provided as flat or planar components of the battery 200, may be wound in a spiral or other configuration, or may be provided in a folded configuration. For example, the electrodes may be wrapped around a relatively rectangular mandrel such that they form an oval wound coil for insertion into a relatively prismatic battery case. According to other exemplary embodiments, the battery may be provided as a button cell battery, a thin film solid state battery, or as another lithium-ion battery configuration.

The battery case (not shown) may be made of stainless steel or another metal. According to an exemplary embodiment, the battery case may be made of titanium, aluminum, or alloys thereof. According to another exemplary embodiment, the battery case may be made of a plastic material or a plastic-foil laminate material (e.g., an aluminum foil provided intermediate a polyolefin layer and a polyester layer).

According to an exemplary embodiment, the negative electrode is coupled to a stainless steel case by a member or tab comprising nickel or a nickel alloy. An aluminum or aluminum alloy member or tab may be coupled or attached to the positive electrode. The nickel and aluminum tabs may serve as terminals for the battery according to an exemplary embodiment.

The dimensions of the battery 200 may differ according to a variety of exemplary embodiments. For example, according to one exemplary embodiment in which the electrodes are wound such that they may be provided in a relatively prismatic battery case, the battery has dimensions of between approximately 30-40 mm by between approximately 20-30 mm by between approximately 5-7 mm. According to another exemplary embodiment, the dimensions of the battery are approximately 20 mm by 20 mm by 3 mm. According to another exemplary embodiment, a battery may be provided in the form of a button cell type battery having a diameter of approximately 30 mm and a thickness of approximately 3 mm. It will be appreciated by those of skill in the art that such dimensions and configurations as are described herein are illustrative only, and that batteries in a wide variety of sizes, shapes, and configurations may be produced in accordance with the novel concepts described herein.

An electrolyte 230 is provided intermediate or between the positive and negative electrodes to provide a medium through which lithium ions may travel. According to an exemplary embodiment, the electrolyte may be a liquid (e.g., a lithium salt dissolved in one or more non-aqueous solvents). According to another exemplary embodiment, the electrolyte may be a lithium salt dissolved in a polymeric material such as poly(ethylene oxide) or silicone. According to another exemplary embodiment, the electrolyte may be an ionic liquid such as N-methyl-N-alkylpyrrolidinium bis(trifluoromethanesulfonyl)imide salts. According to another exemplary embodiment, the electrolyte may be a solid state electrolyte such as a lithium-ion conducting glass such as lithium phosphorous oxynitride (LiPON).

Various other electrolytes may be used according to other exemplary embodiments. For example, according to an exemplary embodiment, the electrolyte may be a 1:1 mixture of ethylene carbonate to diethylene carbonate (EC:DEC) in a 1.0 M salt of LiPF₆. According to another exemplary embodiment, the electrolyte may include a polypropylene carbonate solvent and a lithium bis-oxalatoborate salt (sometimes referred to as LiBOB). According to other exemplary embodiments, the electrolyte may comprise one or more of a PVDF copolymer, a PVDF-polyimide material, and organosilicon polymer, a thermal polymerization gel, a radiation cured acrylate, a particulate with polymer gel, an inorganic gel polymer electrolyte, an inorganic gel-polymer electrolyte, a PVDF gel, polyethylene oxide (PEO), a glass ceramic electrolyte, phosphate glasses, lithium conducting glasses, lithium conducting ceramics, and an inorganic ionic liquid or gel, among others.

A separator 250 is provided intermediate or between the positive electrode 210 and the negative electrode 220. According to an exemplary embodiment, the separator 250 is a polymeric material such as a polypropylene/polyethelene or another polyolefin multilayer laminate that includes micropores formed therein to allow electrolyte and lithium ions to flow from one side of the separator to the other. The thickness of the separator 250 is between approximately 10 micrometers (μm) and 50 μm according to an exemplary embodiment. According to a particular exemplary embodiment, the thickness of the separator is approximately 25 μm and the average pore size of the separator is between approximately 0.02 μm and 0.1 μm.

The positive electrode 210 includes a current collector 212 made of a conductive material such as a metal. According to an exemplary embodiment, the current collector 212 comprises aluminum or an aluminum alloy. According to an exemplary embodiment, the thickness of the current collector 212 is between approximately 5 μm and 75 μm. According to a particular exemplary embodiment, the thickness of the current collector 212 is approximately 20 μm. It should also be noted that while the positive current collector 212 has been illustrated and described as being a thin foil material, the positive current collector may have any of a variety of other configurations according to various exemplary embodiments. For example, the positive current collector may be a grid such as a mesh grid, an expanded metal grid, a photochemically etched grid, or the like.

The current collector 212 has a layer of active material 214 provided thereon (e.g., coated on the current collector). While FIG. 3 shows that the layer of active material 214 is provided on only one side of the current collector 212, it should be understood that a layer of active material similar or identical to that shown as layer 214 may be provided or coated on both sides of the current collector 212.

As shown in FIG. 3, layer 214 includes a primary active material 216 and a secondary or auxiliary active material 218. While the primary active material 216 and the secondary active material 218 are shown as being provided as separate individual layers according to an exemplary embodiment, it will be appreciated that the primary active material 216 and the secondary active material 218 may be provided as a single active material layer in which the primary and secondary active materials are intermixed (see, e.g., the exemplary embodiment shown in FIG. 4, in which layer 214 includes both the primary active material 216 and the secondary active material 218). A binder material may also be utilized in conjunction with the layer of active material 214 to bond or hold the various electrode components together. For example, according to an exemplary embodiment, the layer of active material may include a conductive additive such as carbon black and a binder such as polyvinylidine fluoride (PVDF) or an elastomeric polymer.

According to an exemplary embodiment, the primary active material 216 is a material or compound that includes lithium. The lithium included in the primary active material 216 may be doped and undoped during discharging and charging of the battery, respectively. According to an exemplary embodiment, the primary active material 216 is lithium cobalt oxide (LiCoO₂). According to another exemplary embodiment, the positive active material is of the form LiCo_(x)Ni_((1−x))O₂, where x is between approximately 0.05 and 0.8. According to another exemplary embodiment, the primary active material is of the form LiAl_(x)Co_(y)Ni_((1−x−y))O₂, where x is between approximately 0.05 and 0.3 and y is between approximately 0.1 and 0.3. According to other exemplary embodiments, the primary active material may include LiMn₂O₄.

According to various other exemplary embodiments, the primary active material may include a material such as a material of the form Li_(1−x)MO₂ where M is a metal (e.g., LiCoO₂, LiNiO₂, and LiMnO₂), a material of the form Li_(1−w)(M′_(x)M″_(y))O₂ where M′ and M″ are different metals (e.g., Li(Ni_(x)Mn_(y))O₂, Li(Ni_(1/2)Mn_(1/2))O₂, Li(Cr_(x)Mn_(1−x))O₂, Li(Al_(x)Mn_(1−x))O₂, Li(Co_(x)M_(1−x))O₂, Li(Co_(x)Ni_(1−x))O₂, and Li(Co_(x)Fe_(1−x))O₂)), a material of the form Li_(1−w)(Mn_(x)Ni_(y)CO_(z))O₂ (e.g., LiCo_(x)Mn_(y)Ni_((1−x−y))O₂ Li(Mn_(1/3)Ni_(1/3)Co_(1/3))O₂, Li(Mn_(1/3)Ni_(1/3)Co_(1/3−x)Mg_(x))O₂, Li(Mn_(0.4)Ni_(0.4)Co_(0.2))O₂, and Li(Mn_(0.1)Ni_(0.1)Co_(0.8))O₂), a material of the form Li_(1−w)(Mn_(x)Ni_(x)Co_(1−2x))O₂, a material of the form Li_(1−w)(Mn_(x)Ni_(y)Co_(z)Al_(w))O₂, a material of the form Li_(1−w)(Ni_(x)Co_(y)Al_(z)O) ₂ (e.g., Li(Ni_(0.8)Co_(0.15)Al_(0.05))O₂), a material of the form Li_(1−w)(Ni_(x)Co_(y)M_(z))O₂ where M is a metal, a material of the form Li_(1−w)(Ni_(x)Mn_(y)M_(z))O₂ where M is a metal, a material of the form Li(Ni_(x−y)Mn_(y)Cr_(2−x))O₄, LiMn₂O₄, a material of the form LiM′M″₂O₄ where M′ and M″ are different metals (e.g., LiMn_(2−y−z)Ni_(y), Li_(z)O₄, LiMn_(1.5) Ni_(0.5)O₄, LiNiCuO₄, LiMn_(1−x) Al_(x)O₄, LiNi_(0.5)Ti_(0.5)O₄, and Li_(1.05)Al_(0.1)Mn_(1.85)O_(4−z)F_(z)), Li₂MnO₃, a material of the form Li_(x)V_(y)O_(z) (e.g., LiV₃O₈, LiV₂O₅, and LiV₆O₁₃), a material of the form LiMPO₄ where M is a metal or LiM_(x)′M″_(1−x)PO₄ where M′ and M″ are different metals (e.g., LiFePO₄, LiFe_(x)M_(1−x)PO₄, LiVOPO₄, and Li₃V₂(PO₄)₃, and LIMPO_(4x), where M is a metal such as iron or vanadium and x is a halogen such as fluorine, and combinations thereof.

The secondary active material 218 is a material that is selected to have relatively significant cyclable charge and discharge capacity (i.e., cyclable capacity) below the corrosion potential of the material used for a negative current collector 222 provided as part of the negative electrode 220 (and/or any other material to which the negative current collector is electrically attached or in electrical communication with, for example, a case or housing for the battery) and above the decomposition potential of the primary active material 216. For example, according to an exemplary embodiment in which the negative current collector 222 comprises copper, for which the corrosion potential is approximately 3.5 volts, the secondary active material 218 includes significant charge and discharge capacity below 3.5 volts.

The secondary active material 218 contains electrochemically active lithium in the as-constructed state. According to various exemplary embodiments, the secondary active material may be lithiated forms of the following materials and combinations thereof: V₂O₅, V₆O₁₃, LiMn₂O₄ (spinel), LiM_(x)Mn_((2−x))O₄ (spinel) where M is metal (including Li) and where x is between approximately 0.05 and 0.4, Li₅Ti₄O₁₂, Li_(x)VO₂ (where x is between approximately 0 and 1), V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, and RuO₂.

Where the secondary active material 218 does not include electrochemically cyclable lithium in the as-provided state, electrochemically cyclable lithium may be added to the secondary active material 218 prior to fabrication into cells. The lithium may be added through a chemical or electrochemical process. Such processes could include the addition of butyl lithium or electrical contact with metallic lithium or any other lithium source containing lithium and having an electrochemical potential lower than that of the secondary material (and optionally adding an electrolyte to activate the process). According to another exemplary embodiment, the process may be an electrolytic process, in which the precursor secondary material is polarized to a cathodic potential at which lithium ions present in an electrolyte are inserted into the precursor material. It should also be noted that electrochemically cyclable lithium may be added by adding lithium-containing compounds such as a lithium intermetallic compound such as a lithium-aluminum compound, a lithium-tin compound, a lithium-silicon compound, or any other similar compound that, irreversibly donates lithium at a potential below that of the corrosion potential of the negative current collector (and any material to which it is electrically connected).

According to an exemplary embodiment, the electrochemically active or cyclable lithium may be added as finely divided or powdered lithium. Such powdered lithium may include a passive coating (e.g., a thin layer or film of lithium carbonate) provided thereon to reduce the reactivity of the powdered lithium with air and moisture. Such material may be mixed with the secondary active material prior to application of the secondary active material to fabrication of the cells or may be added as another separate active material layer. According to an exemplary embodiment, the finely divided or powdered lithium particles have a diameter of between approximately 1 μm and 100 μm, and according to a particular embodiment of between approximately 5 μm and 30 μm.

The lithium included in the secondary active material 218 of the positive electrode 210 has significant charge/discharge capacity that lies below the corrosion potential of the negative current collector and/or any battery components to which it is electrically connected (e.g., the case) and above the decomposition potential of the positive electrode active material. The secondary active material contains electrochemically active lithium in the as-constructed state. The lithium becomes significantly doped at a potential below the corrosion potential for the negative current collector 222. In so doing, this material lowers the final potential of the positive electrode in the discharge state, so that the zero voltage crossing potential remains below the corrosion potential of the negative current collector and the battery case. The secondary active material may be capable of releasing the lithium when the battery is charged.

It should be noted that while a variety of materials have been described above as being useful for secondary active material 218, a variety of additional materials may be utilized in addition to or in place of such materials. For example, the secondary active material may comprise an oxide material such as one or more of Li_(x)MoO₃ (0<x≦2), Li_(x)MoO₂ (0<x≦1), Li_(x)Mo₂O₄ (0<x≦2), Li_(x)MnO₂ (0<x≦1), Li_(x)Mn₂O₄ (0<x≦2), Li_(x)V₂O₅ (0<x≦2.5), Li_(x)V₃O₈ (0<x≦3.5), Li_(x)V₆O₁₃ (0<x≦6 for Li_(x)VO_(2.19) and 0<x≦3.6 for Li_(x)VO_(2.17)), Li_(x)VO₂(0<x≦1), Li_(x)WO₃ (0<x≦1), Li_(x)WO₂ (0<x≦1), Li_(x)TiO₂ (anatase) (0<x≦1), Li_(x)Ti₂O₄ (0<x≦2), Li_(x)RuO₂ (0<x≦1), Li_(x)Fe₂O₃ (0<x≦2), Li_(x)Fe₃O₄ (0<x≦2), Li_(x)Cr₂O (0<x≦3), Li_(x)Cr (0<x≦3.8), and Li_(x)Ni_(y)CO_(1−y)O₂ (0<x≦1, 0.90<y≦1.00), where x is selected such that these materials have little or no lithium that becomes undoped below the corrosion potential of the negative current collector during the first charge of the battery.

According to another exemplary embodiment, the secondary active material may comprise a sulfide material such as one or more of Li_(x)V₂S₅ (0<x≦4.8), Li_(x)TaS₂ (0<x≦1), Li_(x)FeS (0<x≦1), Li_(x)FeS₂ (0<x≦1), Li_(x)NbS₃ (0<x≦2.4), Li_(x)MoS₃(0<x≦3), Li_(x)MoS₂ (0<x≦1), Li_(x)TiS₂ (0<x≦1), Li_(x)ZrS₂ (0<x≦1), Li_(x)Fe_(0.25)V_(0.75)S₂ (0<x≦1), Li_(x)Cr_(0.75)V_(0.25)S₂ (0<x≦0.65), and Li_(x)Cr_(0.5)V_(0.5)S₂ (0<x≦1), where x is selected such that these materials have little or no lithium that becomes undoped below the corrosion potential of the negative current collector during the first change of the battery.

According to another exemplary embodiment, the secondary active material may comprise a selenide material such as one or more of Li_(x)NbSe₃ (0<x≦3), Li_(x)VSe₂ (0<x≦1). Various other materials may also be used, for example, Li_(x)NiPS₃ (0<x≦1.5) and Li_(x)FePS₃ (0<x≦1.5), where x is selected such that these materials have little or no lithium that becomes undoped below the corrosion potential of the negative current collector during the first change of the battery.

According to an exemplary embodiment, the thickness of the layer of active material 214 is between approximately 0.1 μm and 3 mm. According to another exemplary embodiment, the thickness of the layer of active material 214 is between approximately 25 μm and 300 μm. According to a particular exemplary embodiment, the thickness of the layer of active material 214 is approximately 75 μm. In embodiments in which the primary active material 216 and the secondary active material 218 are provided as separate layers of active material, the thickness of the primary active material 216 is between approximately 25 μm and 300 μm (and approximately 75 μm according to a particular exemplary embodiment), while the thickness of the secondary active material 218 is between approximately 5 μm and 60 μm (and approximately 10 μm according to a particular exemplary embodiment).

The amount of the secondary active material 218 to be added is determined by the electrochemical equivalents (i.e., capacity) of lithium that can be cycled from that material. According to an exemplary embodiment, the amount is as small as practical, because this minimizes the amount to which the battery's average operating voltage (and therefore energy density) is reduced. According to another exemplary embodiment, the amount is at a minimum equal to the difference between the irreversible capacity of the negative electrode active material and that of the positive active material.

The negative current collector 222 included as part of the negative electrode 220 is made of a conductive material such as a metal. According to an exemplary embodiment, the current collector 222 is copper or a copper alloy. According to another exemplary embodiment, the current collector 222 is titanium or a titanium alloy. According to another exemplary embodiment, the current collector 222 is nickel or a nickel alloy. According to another exemplary embodiment in which the negative active material 224 is not carbon, the current collector 222 is aluminum or an aluminum alloy. It should also be noted that while the negative current collector 222 has been illustrated and described as being a thin foil material, the positive current collector may have any of a variety of other configurations according to various exemplary embodiments. For example, the positive current collector may be a grid such as a mesh grid, an expanded metal grid, a photochemically etched grid, or the like.

According to an exemplary embodiment, the thickness of the current collector 222 is between approximately 100 nm and 100 μm. According to another exemplary embodiment, the thickness of the current collector 222 is between approximately 5 μm and 25 μm. According to a particular exemplary embodiment, the thickness of the current collector 222 is approximately 10 μm.

The negative current collector 222 has a negative active material 224 provided thereon. While FIG. 3 shows that the active material 224 is provided on only one side of the current collector 222, it should be understood that a layer of active material similar or identical to that shown may be provided or coated on both sides of the current collector 222.

According to an exemplary embodiment, the negative active material is a carbonaceous material (e.g., carbon). According to another exemplary embodiment, the negative active material 224 is a lithium titanate material such as Li₄Ti₅O₁₂. Other lithium titanate materials which may be suitable for use as the negative active material may include one or more of include the following lithium titanate spinel materials: H_(x)Li_(y−x)TiO_(x)O₄, H_(x)Li_(y−x)TiO_(x)O₄, Li₄M_(x)Ti_(5−x)O₁₂, Li_(x)Ti_(y)O₄, Li_(x)Ti_(y)O₄, Li₄[Ti_(1.67)Li_(0.33−y)M_(y)]O₄, Li₂TiO₃, Li₄Ti_(4.75)V_(0.25)O₁₂, Li₄Ti_(4.75)Fe_(0.25)O_(11.88), and Li₄Ti_(4.5)Mn_(0.5)O₁₂, and LiM′M″XO₄ (where M′ is a metal such as nickel, cobalt, iron, manganese, vanadium, copper, chromium, molybdenum, niobium, or combinations thereof), M″ is an optional three valent non-transition metal, and X is zirconium, titanium, or a combination of these two. Note that such lithium titanate spinel materials may be used in any state of lithiation (e.g., Li_(4+x)Ti₅O₁₂, where 0<x≦3).

One advantage of using a lithium titanate material instead of a carbonaceous material is that it is believed that the use of a lithium titanate material allows for charging and discharging of the battery at higher rates than is capable using carbonaceous materials. Lithium titanate materials are also believed to offer superior cycle life because they are so called “zero-strain” materials. Zero strain materials have crystal lattices which do not experience shrinkage or contraction with lithium doping/de-doping, making them free from strain-related degradation mechanisms. According to other exemplary embodiments, the negative active material 224 may be carbon, Li_(x)Al, Li_(x)Sn, Li_(x)Si, Li_(x)SnO, metal nanoparticle composites (e.g., including Li_(x)Al, Li_(x)Sn, Li_(x)Si, or Li_(x)SnO), or carbon-coated lithium titanate.

Another advantageous feature of using a lithium titanate material is that it is believed that when used in a negative electrode of a lithium-ion battery, such materials will cycle lithium at a potential plateau of about 1.5 V versus a lithium reference electrode. This is substantially higher than graphitic carbon, which is traditionally used in lithium ion batteries, and cycles lithium down to about 0.1 V in the fully charged state. As a result, the battery using lithium titanate is believed to be less likely to result in plating of lithium (which occurs at 0 V versus a lithium reference) while being charged. Lithium plating is a well-known phenomenon that can lead to loss in performance of lithium ion batteries. Being free from the risk lithium plating, cells with lithium titanate negative electrodes may also be charged at rates that exceed those with carbon negative electrodes. For example, a common upper limit for the rate of charge in lithium ion batteries is about 1 C (meaning that the battery can be fully charged from the discharged state in one hour). Conversely, it has been reported in literature that lithium titanate may be charged at rates up to 10 C (i.e., attaining full charge in 1/10 hour, or six minutes). Being able to recharge a battery more quickly substantially increases the functionality of devices that employ such a battery. A further advantage of the higher potential of the lithium titanate material is that it avoids decomposition of organic solvents (such as propylene carbonate) commonly used in lithium ion batteries. In so doing, it may reduce negative consequences such as formation of gas, cell swelling, reduction of reversible battery capacity, and buildup of resistive films which reduce battery power.

A binder material may also be utilized in conjunction with the layer of active material 224. For example, according to an exemplary embodiment, the layer of active material may include a conductive additive such as carbon black and a binder such as polyvinylidine fluoride (PVDF) or an elastomeric polymer.

According to various exemplary embodiments, the thickness of the active material 224 is between approximately 0.1 μm and 3 mm. According to other exemplary embodiments, the thickness of the active material 224 may be between approximately 25 μm and 300 μm. According to another exemplary embodiment, the thickness of the active material 224 may be between approximately 20 μm and 90 μm, and according to a particular exemplary embodiment, approximately 75 μm.

FIG. 5 is a graph 300 illustrating the theoretical charging and discharging behavior for a lithium-ion battery constructed in accordance with an exemplary embodiment such as that shown and described with regard to FIG. 3. Curve 310 represents the electrode potential versus a lithium reference electrode for a positive electrode (e.g., positive electrode 210) that includes an aluminum current collector having a LiCoO₂ primary active material and a secondary active material provided thereon.

The secondary active material is selected to provide significant charging/discharging capacity below the corrosion potential (shown as dashed line 322) of the negative current collector and above the decomposition potential (shown as dashed line 312) of the LiCoO₂ primary active material. According to various exemplary embodiments, the secondary active material may be lithiated forms of the following materials and combinations thereof: V₂O₅, V₆O₁₃, LiMn₂O₄ (spinel), LiM_(x)Mn_((2−x))O₄ (spinel) where M is metal (including Li) and where x is between approximately 0 and 2, Li₅Ti₄O₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, and RuO₂.

Curve 320 represents the electrode potential versus a lithium reference electrode for a negative electrode during charging that includes a copper current collector having a lithium titanate material (i.e., Li₄Ti₅O₁₂) active material provided thereon. The difference between curves 310 and 320 is representative of the overall cell voltage of the battery.

As shown in FIG. 5, upon initial charging to full capacity, the potential of the positive electrode, as shown by curve 310, increases from approximately 2.1 volts (shown as point 311) to a point above the corrosion potential of copper used to form the negative current collector (designated by dashed line 322). The potential of the negative electrode decreases from approximately 3.0 volts to a point below the decomposition potential of the LiCoO₂ active material provided on the positive current collector (designated by dashed line 312). According to an exemplary embodiment, the corrosion potential of copper is approximately 3.5 volts. The predicted decomposition potential of the LiCoO₂ active material is approximately 1.6 volts. According to an experimentally observed exemplary embodiment, the decomposition potential of the LiCoO₂ active material is approximately 1.35 volts.

Upon subsequent discharging of the battery, the negative electrode potential follows a path designated by line 326. However, because the secondary active material is chosen to have significant charging/discharging capacity below the corrosion potential of the negative current collector and above the decomposition potential of the LiCoO₂ primary active material, and because a Li₄Ti₅O₁₂ active material is provided thereon the negative current collector, the zero voltage crossing potential (shown as point 330) is below the corrosion potential of the negative current collector and above the decomposition potential of the LiCoO₂ primary active material, thus avoiding corrosion of the negative current collector (and potentially of the battery case) and any associated loss of battery charging capacity.

The charging/discharging behavior of the primary and secondary active materials (e.g., primary active material 216 and secondary active material 218) provided on the positive current collector are shown in FIG. 5 as two portions 314,316 of curve 310. Portion 314 of curve 310 represents the charging/discharging behavior of the positive electrode due to the doping and undoping of the primary active material (i.e., LiCoO₂), while portion 316 of curve 310 represents the charging/discharging behavior of the positive electrode due to the doping and undoping of the secondary active material (i.e., lithiated V₆O₁₃, LiMn₂O₄, etc.). Upon charging of the battery, the positive electrode potential begins at point 311 (corresponding to approximately 2.1 volts) and proceeds to the right on the graph as charging proceeds. When the battery is subsequently discharged, the potential of the positive electrode proceeds from right to left in the graph such that it proceeds from the portion 314 of the curve 310 to the portion 316 of the curve 310.

It is intended that a lithium-ion battery such as that described herein may be fully discharged while the materials for both electrodes, including their corresponding current collectors, are stable (e.g., corrosion of the current collectors and/or the decomposition of active material may be avoided, etc.). One potential advantageous feature of such an arrangement is that the occurrence of reduced device functionality (i.e., the need to recharge more frequently) and corrosion of the current collectors and battery case (with the incumbent possibility of leaking potentially corrosive and toxic battery contents) may be reduced or avoided. Another advantageous feature of such an arrangement is that the battery may be repeatedly cycled (i.e., charged and discharged) to near-zero-voltage conditions without significant decline in battery performance.

Various advantageous features may be obtained by utilizing batteries such as those shown and described herein. For example, use of such batteries may eliminate the need to utilize circuitry to disconnect batteries approaching near-zero voltage conditions. By not utilizing circuitry for this function, volume and cost reductions may be obtained.

According to an exemplary embodiment, lithium-ion batteries such as those described above may be used in conjunction with medical devices such as medical devices that may be implanted in the human body (referred to as “implantable medical devices” or “IMD's”).

FIG. 6 illustrates a schematic view of a system 400 (e.g., an implantable medical device) implanted within a body or torso 432 of a patient 430. The system 400 includes a device 410 in the form of an implantable medical device that for purposes of illustration is shown as a defibrillator configured to provide a therapeutic high voltage (e.g., 700 volt) treatment for the patient 430.

The device 410 includes a container or housing 414 that is hermetically sealed and biologically inert according to an exemplary embodiment. The container may be made of a conductive material. One or more leads 416 electrically connect the device 410 and to the patient's heart 420 via a vein 422. Electrodes 417 are provided to sense cardiac activity and/or provide an electrical potential to the heart 420. At least a portion of the leads 416 (e.g., an end portion of the leads shown as exposed electrodes 417) may be provided adjacent or in contact with one or more of a ventricle and an atrium of the heart 420.

The device 410 includes a battery 450 provided therein to provide power for the device 410. According to another exemplary embodiment, the battery 450 may be provided external to the device or external to the patient 430 (e.g., to allow for removal and replacement and/or charging of the battery). The size and capacity of the battery 450 may be chosen based on a number of factors, including the amount of charge required for a given patient's physical or medical characteristics, the size or configuration of the device, and any of a variety of other factors. According to an exemplary embodiment, the battery is a 5 mAh battery. According to another exemplary embodiment, the battery is a 300 mAh battery. According to various other exemplary embodiments, the battery may have a capacity of between approximately 10 and 100 mAh.

According to other exemplary embodiments, more than one battery may be provided to power the device 410. In such exemplary embodiments, the batteries may have the same capacity or one or more of the batteries may have a higher or lower capacity than the other battery or batteries. For example, according to an exemplary embodiment, one of the batteries may have a capacity of approximately 500 mAh while another of the batteries may have a capacity of approximately 75 mAh.

According to another exemplary embodiment shown in FIG. 7, an implantable neurological stimulation device 500 (an implantable neuro stimulator or INS) may include a battery 502 such as those described above with respect to the various exemplary embodiments. Examples of some neuro stimulation products and related components are shown and described in a brochure titled “Implantable Neurostimulation Systems” available from Medtronic, Inc.

An INS generates one or more electrical stimulation signals that are used to influence the human nervous system or organs. Electrical contacts carried on the distal end of a lead are placed at the desired stimulation site such as the spine or brain and the proximal end of the lead is connected to the INS. The INS is then surgically implanted into an individual such as into a subcutaneous pocket in the abdomen, pectoral region, or upper buttocks area. A clinician programs the INS with a therapy using a programmer. The therapy configures parameters of the stimulation signal for the specific patient's therapy. An INS can be used to treat conditions such as pain, incontinence, movement disorders such as epilepsy and Parkinson's disease, and sleep apnea. Additional therapies appear promising to treat a variety of physiological, psychological, and emotional conditions. Before an INS is implanted to deliver a therapy, an external screener that replicates some or all of the INS functions is typically connected to the patient to evaluate the efficacy of the proposed therapy.

The INS 500 includes a lead extension 522 and a stimulation lead 524. The stimulation lead 524 is one or more insulated electrical conductors with a connector 532 on the proximal end and electrical contacts (not shown) on the distal end. Some stimulation leads are designed to be inserted into a patient percutaneously, such as the Model 3487A Pisces-Quad® lead available from Medtronic, Inc. of Minneapolis Minn., and stimulation some leads are designed to be surgically implanted, such as the Model 3998 Specify® lead also available from Medtronic.

Although the lead connector 532 can be connected directly to the INS 500 (e.g., at a point 536), typically the lead connector 532 is connected to a lead extension 522. The lead extension 522, such as a Model 7495 available from Medtronic, is then connected to the INS 500.

Implantation of an INS 520 typically begins with implantation of at least one stimulation lead 524, usually while the patient is under a local anesthetic. The stimulation lead 524 can either be percutaneously or surgically implanted. Once the stimulation lead 524 has been implanted and positioned, the stimulation lead's 524 distal end is typically anchored into position to minimize movement of the stimulation lead 524 after implantation. The stimulation lead's 524 proximal end can be configured to connect to a lead extension 522.

The INS 500 is programmed with a therapy and the therapy is often modified to optimize the therapy for the patient (i.e., the INS may be programmed with a plurality of programs or therapies such that an appropriate therapy may be administered in a given situation). In the event that the battery 502 requires recharging, an external lead (not shown) may be used to electrically couple the battery to a charging device or apparatus.

A physician programmer and a patient programmer (not shown) may also be provided to allow a physician or a patient to control the administration of various therapies. A physician programmer, also known as a console programmer, uses telemetry to communicate with the implanted INS 500, so a clinician can program and manage a patient's therapy stored in the INS 500, troubleshoot the patient's INS 500 system, and/or collect data. An example of a physician programmer is a Model 7432 Console Programmer available from Medtronic. A patient programmer also uses telemetry to communicate with the INS 500, so the patient can manage some aspects of her therapy as defined by the clinician. An example of a patient programmer is a Model 7434 Itrel® 3 EZ Patient Programmer available from Medtronic.

While the medical devices described herein (e.g., systems 400 and 500) are shown and described as a cardiac defibrillator and a neurological stimulation device, it should be appreciated that other types of implantable medical devices may be utilized according to other exemplary embodiments, such as cardiac pacemakers, cardioverters, cardiac contractility modulators, drug administering devices, diagnostic recorders, hearing aids, sensors, telemetry devices, cochlear implants, and the like for alleviating the adverse effects of various health ailments. According to still other embodiments, non-implantable medical devices or other types of devices may utilize batteries as are shown and described in this disclosure.

It is also contemplated that the medical devices described herein may be charged or recharged when the medical device is implanted within a patient. That is, according to an exemplary embodiment, there is no need to disconnect or remove the medical device from the patient in order to charge or recharge the medical device. For example, transcutaneous energy transfer (TET) may be used, in which magnetic induction is used to deliver energy from outside the body to the implanted battery, without the need to make direct physical contact to the implanted battery, and without the need for any portion of the implant to protrude from the patient's skin. According to another exemplary embodiment, a connector may be provided external to the patient's body that may be electrically coupled to a charging device in order to charge or recharge the battery. According to other exemplary embodiments, medical devices may be provided that may require removal or detachment from the patient in order to charge or recharge the battery.

It should be understood that while the present disclosure describes the use of lithium-ion batteries with a variety of medical devices, such batteries may be used in a variety of other applications, including computers (e.g., laptop computers), phones (e.g., cellular, mobile, or cordless phones), automobiles, and any other device or application for which it may be advantageous to provide power in the form of a lithium-ion battery.

It is also important to note that the construction and arrangement of the lithium-ion battery as shown and described with respect to the various exemplary embodiments is illustrative only. Although only a few embodiments of the present inventions have been described in detail in this disclosure, those skilled in the art who review this disclosure will readily appreciate that many modifications are possible (e.g., variations in sizes, dimensions, structures, shapes and proportions of the various elements, values of parameters, mounting arrangements, use of materials, colors, orientations, etc.) without materially departing from the novel teachings and advantages of the subject matter recited in the claims. Accordingly, all such modifications are intended to be included within the scope of the present invention as defined in the appended claims. Other substitutions, modifications, changes and omissions may be made in the design, operating conditions and arrangement of the preferred and other exemplary embodiments without departing from the scope of the present invention as expressed in the appended claims. 

1. A medical device comprising: a rechargeable lithium-ion battery for providing power to the medical device, the lithium-ion battery comprising: a positive electrode comprising a current collector, a first active material, and a second active material; and a negative electrode comprising a current collector and a third active material, the third active material comprising a titanate material; wherein the first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions; and wherein the second active material exhibits charging and discharging capacity below a corrosion potential of the current collector of the negative electrode and above a decomposition potential of the first active material; wherein the battery has a capacity between approximately 10 mAh and 1000 mAh.
 2. The medical device of claim 1, wherein at least a portion of the medical device is configured for implantation into a body of a patient.
 3. The medical device of claim 2, wherein a portion of the medical device including the lithium-ion battery is implanted within the body of the patient and wherein the lithium-ion battery may be charged without removing the lithium-ion battery from the body of the patient.
 4. The medical device of claim 1, wherein the medical device comprises a neurological stimulation device.
 5. The medical device of claim 4, wherein the neurological stimulation device is configured to provide a therapeutic treatment to a patient by electrically stimulating a portion of at least one of a patient's brain and a patient's spine.
 6. The medical device of claim 5, wherein the neurological stimulation device is programmed to selectively provide a plurality of therapeutic treatments to a patient.
 7. The medical device of claim 1, wherein the medical device is selected from the group consisting of a cardiac defibrillator, a cardiac pacemaker, a cardiac contractility modulator, a cardioverter, a drug administration device, a cochlear implant, a hearing aid, a sensor, a telemetry device, and a diagnostic recorder.
 8. The medical device of claim 7, wherein the medical device is an implantable cardiac defibrillator for providing a therapeutic voltage treatment to a patient.
 9. The medical device of claim 8, further comprising at least one lead extending from the cardiac defibrillator and configured to electrically stimulate a portion of a patient's heart.
 10. The medical device of claim 9, wherein the first active material comprises a lithium titanate material.
 11. A medical device comprising: a rechargeable lithium-ion battery for providing power to the medical device, the lithium-ion battery comprising: a positive electrode comprising a current collector, a first active material, and a second active material; and a negative electrode comprising a current collector and a third active material, the third active material comprising a titanate material; wherein the first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions; and wherein the second active material exhibits charging and discharging capacity below a corrosion potential of the current collector of the negative electrode and above a decomposition potential of the first active material; wherein the titanate material comprises a lithium titanate material.
 12. The medical device of claim 11, wherein the current collector of the negative electrode comprises at least one of copper, titanium, nickel, and aluminum.
 13. The medical device of claim 11, wherein the second active material comprises a lithiated form of V₆O₁₃.
 14. The medical device of claim 11, wherein the second active material comprises a lithiated form of LiMn₂O₄.
 15. The medical device of claim 11, wherein the second active material comprises a material selected from the group consisting of lithiated forms of V₂O₅, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof.
 16. A medical device comprising: a rechargeable lithium-ion battery for providing power to the medical device, the lithium-ion battery comprising: a positive electrode comprising a current collector, a first active material, and a second active material; and a negative electrode comprising a current collector and a third active material, the third active material comprising a titanate material; wherein the first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions; and wherein the second active material exhibits charging and discharging capacity below a corrosion potential of the current collector of the negative electrode and above a decomposition potential of the first active material; wherein the first active material comprises at least one of a material of the form LiCo_(x)Ni_((1−x−y))O_(2,) a material in the form LiNi_(x)Co_(y)Al_(z)O₂, and a material in the form LiCo_(x)Mn_(y)Ni_((1−x−y))O₂.
 17. The medical device of claim 16, wherein the negative current collector comprises copper.
 18. The medical device of claim 17, wherein the second active material comprises at least one of a lithiated form of V₆O₁₃ and a lithiated form of LiMn₂O₄.
 19. The medical device of claim 17, wherein the second active material comprises a material selected from the group consisting of lithiated forms of V₂O₅, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof.
 20. A device for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a rechargeable battery for providing power to the device, the battery comprising: a positive current collector; a negative current collector; an active material layer provided on the positive current collector, the active material layer comprising a first active material for doping and de-doping lithium ions and a second active material for doping and de-doping lithium ions, the second active material exhibiting charge and discharge capacity below a corrosion potential of the negative current collector, the second active material being lithiated such that it includes electrochemically active lithium; and a third active material comprising a lithium titanate material provided on the negative current collector for doping and de-doping lithium ions; wherein the battery has a capacity between approximately 10 mAh and 1000 mAh.
 21. The device of claim 20, wherein at least a portion of the device is configured for implantation into a body of a patient.
 22. The device of claim 20, wherein the device comprises a neurological stimulation device.
 23. The device of claim 22, wherein the neurological stimulation device is programmed to selectively provide a plurality of therapeutic treatments to a patient.
 24. The device of claim 20, wherein the device is selected from the group consisting of a cardiac defibrillator, a cardiac pacemaker, a cardioverter, a cardiac contractility modulator, a drug administration device, a cochlear implant, a hearing aid, a sensor, a telemetry device, and a diagnostic recorder.
 25. The device of claim 24, wherein the device is an implantable cardiac defibrillator for providing a therapeutic high voltage treatment to a patient.
 26. The device of claim 20, wherein the lithium titanate material comprises Li₄Ti₅O₁₂.
 27. The device of claim 20, wherein the first active material comprises a material selected from the group consisting of LiCoO₂, a material of the form LiCo_(x)Ni_((1−x))O₂, a material in the form LiNi_(x)Co_(y)Al_(z)O₂, and combinations thereof.
 28. The device of claim 27, wherein the negative current collector comprises copper.
 29. The device of claim 28, wherein the second active material comprises a material selected from the group consisting of lithiated forms of V₂O₅, LiMn₂O₄, V₆O₁₃, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof.
 30. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; is whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery; wherein the lithium-ion battery has a capacity between approximately 10 mAh and 1000 mAh.
 31. The system of claim 30, wherein at least a portion of the system is implanted into a body of a patient.
 32. The system of claim 31, wherein the lithium-ion battery may be charged without removing the system from the body of the patient.
 33. The system of claim 30, wherein the system comprises a neurological stimulation device.
 34. The system of claim 30, wherein the system includes a device selected from the group consisting of a cardiac defibrillator, a cardiac pacemaker, a cardiac contractility modulator, a cardioverter, a drug administration device, a cochlear implant, a hearing aid, a sensor, a telemetry device, and a diagnostic recorder.
 35. The system of claim 34, wherein the device is an implantable cardiac defibrillator for providing a therapeutic voltage treatment to a patient.
 36. The system of claim 30, wherein the primary active material comprises LiCoO₂.
 37. The system of claim 36, wherein the current collector of the negative electrode comprises copper.
 38. The system of claim 30, wherein the lithium-ion battery has a capacity of approximately 100 mAh.
 39. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; wherein the primary active material comprises LiCoO₂; and wherein the current collector of the negative electrode comprises titanium; whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery.
 40. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; wherein the primary active material comprises LiCoO₂; and wherein the secondary active material comprises a lithiated form of V₆O₁₃; whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery.
 41. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; is wherein the primary active material comprises LiCoO₂; and wherein the secondary active material comprises a lithiated form of LiMn₂O₄; whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery.
 42. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; is wherein the primary active material comprises LiCoO₂; and wherein the secondary active material comprises a material selected from the group consisting of lithiated forms of V₂O₅, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof; whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery.
 43. A system for providing at least one of a therapeutic treatment and a diagnostic function to a patient comprising: a lithium-ion battery configured to provide power to the system and being capable of being charged and discharged, the lithium-ion battery comprising: a negative electrode having a current collector comprising copper and an active material comprising a titanate material provided thereon; and a positive electrode comprising a current collector comprising aluminum having a primary active material and a secondary active material provided on at least one side thereof, the secondary active material comprising a lithiated form of a material configured to provide charging and discharging capacity for the positive electrode below a corrosion potential of the negative current collector and above a decomposition potential of the primary active material; and a polymeric separator provided intermediate the positive electrode and the negative electrode; whereby the lithium-ion battery may be discharged to near-zero-voltage conditions without degradation to the cyclable capacity of the battery.
 44. A method of treating a medical condition of a patient comprising: providing at least a portion of a medical device in contact with the patient; and providing power to the medical device from a battery such that the medical device provides a therapeutic treatment to the patient; wherein the battery comprises: a positive electrode comprising a positive current collector, a first active material, and a second active material; and a negative electrode comprising a negative current collector and a third active material, the third active material comprising a lithium titanate material; wherein the first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions; and wherein the second active material exhibits charging and discharging capacity below a corrosion potential of the negative current collector and above a decomposition potential of the first active material; wherein the battery has a capacity between approximately 10 mAh and 1000 mAh.
 45. The method of claim 44, wherein the step of providing at least a portion of a medical device in contact with the patient comprises implanting at least a portion of the medical device in the patient.
 46. The method of claim 45, further comprising charging the battery without removing the implanted portion of the medical device from the body of the patient.
 47. The method of claim 44, wherein the medical device comprises a neurological stimulation device.
 48. The method of claim 47, further comprising providing a therapeutic treatment to a patient by electrically stimulating a portion of at least one of a patient's brain and a patient's spine.
 49. The method of claim 48, further comprising selectively providing a plurality of therapeutic treatments to the patient.
 50. The method of claim 44, wherein the medical device is selected from the group consisting of a defibrillator, a pacemaker, a cardiac contractility modulator, a cardioverter, a drug administration device, a cochlear implant, a hearing aid, a sensor, a telemetry device, and a diagnostic recorder.
 51. The method of claim 50, wherein the device is an implantable defibrillator and further comprising providing a therapeutic voltage treatment to a patient.
 52. The method of claim 44, wherein the positive electrode and the negative electrode have a zero voltage-crossing potential below the corrosion potential of the negative current collector and above the decomposition potential of the first active material.
 53. The method of claim 44, wherein the first active material comprises lithium.
 54. The method of claim 53, wherein the first active material comprises LiCoO₂.
 55. The method of claim 54, wherein the negative current collector comprises at least one of copper and titanium.
 56. The method of claim 54, wherein the second active material comprises a lithiated form of V₆O₁₃.
 57. The method of claim 54, wherein the second active material comprises a lithiated form of LiMn₂O₄.
 58. The method of claim 54, wherein the second active material comprises a material selected from the group consisting of lithiated forms of V₂ 05, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof.
 59. A method of treating a medical condition of a patient comprising: providing at least a portion of a medical device in contact with the patient; and providing power to the medical device from a battery such that the medical device provides a therapeutic treatment to the patient; wherein the battery comprises: a positive electrode comprising a positive current collector, a first active material, and a second active material; and a negative electrode comprising a negative current collector and a third active material, the third active material comprising a lithium titanate material; wherein the first active material, second active material, and third active materials are configured to allow doping and undoping of lithium ions; and wherein the second active material exhibits charging and discharging capacity below a corrosion potential of the negative current collector and above a decomposition potential of the first active material; and wherein the first active material comprises a material selected from the group consisting of a material of the form LiCo_(x)Ni_((1−x))O₂, a material of the form LiNi_(x)Co_(y)Al_(z)O₂, and combinations thereof.
 60. The method of claim 59, wherein the negative current collector comprises copper.
 61. The method of claim 60, wherein the second active material comprises a lithiated form of a material selected from the group consisting of V₆O₁₃ and LiMn₂O₄.
 62. The method of claim 60, wherein the second active material comprises a material selected from the group consisting of lithiated forms of V₂O₅, Li₅Ti₄O₁₂, Li_(x)VO₂, V₃O₈, MoO₃, TiS₂, WO₂, MoO₂, RuO₂, LiM_(x)Mn_((2−x))O₄, and combinations thereof. 